Get started

Healthcarestocks

TSOI PUMPIN'!!!I moved another trader profitably out of TSOI on the last run and waited for it to base the Honey Bucket before buying in myself. This stock is a beauty for pump action and I suspect that whoever is moving it, either wanted to take a year end loss and then re-accumulate or bears had it by the short & curlys, dunno. I care less about the fundamentals on stocks like this and tend to trade on pure technicals. Still holding 1/2 my stash after a quick one day 100% and waiting to see if it Fibs out well like last time. As always, "Not investment advice", DYOR and good luck!
OTC:TSOI
by FudBox
6
Healthcare is still in a bull market - be longAt the start of 2022, healthcare stocks have gotten killed, especially anything that was a winner in the past 1-2 years. A lot of people are getting rather bearish, but they shouldn't be. The fundamentals favor healthcare still in many ways, and momentum is still rather strong. We already got the breakout in healthcare stocks, and we just got the retest, which was enough to scare a lot of people out. Now is a great entry for a long position, coming out of a short consolidation into a potential new bull phase.
AMEX:XLVLong
by GTStockmaster
Speculative Grade LongI rarely dabble in health service companies. But, after doing some reading I see a lot of merit in their mission, and this company could easily be worth 10X its current market capitalization if utilized by the Health service industry or acquired by an insurers to cut liability costs. Little can be distilled from available chart data, and comprehending the fundamentals for this sector are beyond my expertise. I am looking at this company as a speculative grade holding to diversify the portfolio a bit into the health service sector. seekingalpha.com seraprognostics.com www.360dx.com *TA interpretation + personal opinion = not investment advice
NASDAQ:SERALong
by kingmidasLXIX
BFLY Price Target $20BFLY Current Price $12.20 Price Target $20 I like BFLY here, as it has over $500 million in cash following its merger with Longview, and I like that it is fully expected to be cash-flow positive by 2024.Revenue increased 40.0% to $16.5 million in Q2 2021 from $11.8 million in Q2 2020. The revenue can be traced to both product and subscription revenues. Product revenue increased 30.3% to $13.0 million from $10.0 million last year. That is solid. The company is focused heavily on improving subscriptions, and it is translating to sales. Subscription revenue increased 94.3% to $3.5 million from $1.8 million last year. I see this line of revenue growing sizably in the coming quarters as it becomes a bigger focus of the company. With a half of billion in cash BFLY has significant funds to continue growing their customer base with their innovative cost cutting products. Their Butterfly IQ+ is a handheld ultrasound which is cutting the cost of ultrasounds by over 90%, this opens up the opportunity for the company to expand to developing countries with this amazing cost cutting innovation.
NYSE:BFLYLong
by Value-Invest
XLV - an attractive buy The pandemic has opened up investing opportunities in the healthcare sector. While buying stock in major companies may be attractive, I feel that investing in healthcare ETF (XLV) may be a better and more conservative option. XLV recently hit a 52 week high but as you can see it has been pulling back (perhaps in part due to the uncertainty caused by the delta variant). I see significant support between 133.70-134.40 nearby and will be watching price action closely to enter a long trade. If you like my analysis, please give it a “thumbs up” and follow me to get immediate notifications. Always use sound money and risk management in all your trades.
AMEX:XLVLong
by Trading_Vista
Whatever WORX Right?WORX stock tested a key FIb level on Wednesday being the 50 fib line after plotting the top anchor at the recent high the first time WORX busted above the 50 fib. Before this latest round of testing, the last time WORX reached this key level it was rejected heavily. A few weeks ago, the company announced that it had regained compliance with the NASDAQ listing requirements. At the same time, it announced that Tim Hannibal, current COO, would become the new CEO. He stated that “over the last 10-15 years, technology within the healthcare industry has evolved both in cost and complexity. Unfortunately, the technology which was implemented within different hospital departments and with disparate objectives has failed to provide the promised advancements.” As a leader in providing software to healthcare institutions, there is a clear benefit that Scworx could gain from the pandemic’s current state and the ending of Covid-19. With all of this in mind, is WORX stock worth keeping an eye on? Quote source and read more: 4 Epicenter Penny Stocks You Need to Know About in 2021
NASDAQ:WORX
by PennyStocks101